Biodexa Pharmaceticals Net Worth
Biodexa Pharmaceticals Net Worth Breakdown | BDRX |
Biodexa Pharmaceticals Net Worth Analysis
Biodexa Pharmaceticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Biodexa Pharmaceticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Biodexa Pharmaceticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Biodexa Pharmaceticals' net worth analysis. One common approach is to calculate Biodexa Pharmaceticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Biodexa Pharmaceticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Biodexa Pharmaceticals' net worth. This approach calculates the present value of Biodexa Pharmaceticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Biodexa Pharmaceticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Biodexa Pharmaceticals' net worth. This involves comparing Biodexa Pharmaceticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Biodexa Pharmaceticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Biodexa Pharmaceticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biodexa Pharmaceticals' net worth research are outlined below:
| Biodexa Pharmaceticals generated a negative expected return over the last 90 days | |
| Biodexa Pharmaceticals has high historical volatility and very poor performance | |
| Biodexa Pharmaceticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 381 K. Net Loss for the year was (7.08 M) with loss before overhead, payroll, taxes, and interest of (4.41 M). | |
| Biodexa Pharmaceticals generates negative cash flow from operations | |
| Biodexa Pharmaceticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Result of General Meeting |
Biodexa Pharmaceticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biodexa Pharmaceticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biodexa Pharmaceticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Follow Biodexa Pharmaceticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.89 M.Market Cap |
|
Project Biodexa Pharmaceticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.93) | (0.98) | |
| Return On Capital Employed | (1.61) | (1.53) | |
| Return On Assets | (0.67) | (0.71) | |
| Return On Equity | (1.51) | (1.59) |
When accessing Biodexa Pharmaceticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Biodexa Pharmaceticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biodexa Pharmaceticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Biodexa Pharmaceticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biodexa Pharmaceticals. Check Biodexa Pharmaceticals' Beneish M Score to see the likelihood of Biodexa Pharmaceticals' management manipulating its earnings.
Evaluate Biodexa Pharmaceticals' management efficiency
Biodexa Pharmaceticals has return on total asset (ROA) of (0.3752) % which means that it has lost $0.3752 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9723) %, meaning that it created substantial loss on money invested by shareholders. Biodexa Pharmaceticals' management efficiency ratios could be used to measure how well Biodexa Pharmaceticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.98 in 2024. Return On Capital Employed is likely to rise to -1.53 in 2024. At this time, Biodexa Pharmaceticals' Total Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 3.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 3.3 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 148.11 | 140.70 | |
| Tangible Book Value Per Share | 54.99 | 52.24 | |
| Enterprise Value Over EBITDA | 0.54 | 0.56 | |
| Price Book Value Ratio | 0.36 | 0.34 | |
| Enterprise Value Multiple | 0.54 | 0.56 | |
| Price Fair Value | 0.36 | 0.34 | |
| Enterprise Value | -3.8 M | -3.7 M |
The strategic initiatives led by Biodexa Pharmaceticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 4.6966 | Revenue 83 K | Quarterly Revenue Growth (0.64) | Revenue Per Share 0.435 | Return On Equity (0.97) |
Biodexa Pharmaceticals Corporate Filings
13A | 20th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
6K | 12th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 5th of November 2024 Other Reports | ViewVerify | |
| 12th of August 2024 Other Reports | ViewVerify |
Biodexa Pharmaceticals Earnings per Share Projection vs Actual
Biodexa Pharmaceticals Corporate Management
| Nicola Tuckwell | VP Operations | Profile | |
| Dmitry MD | Chief Officer | Profile | |
| Daniel MBA | Vice Technology | Profile | |
| Fiona Sharp | Group Controller | Profile | |
| Steve Ellul | Chief Officer | Profile |
Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.